Investigation of Fenebrutinib Metabolism and Bioactivation Using MS(3) Methodology in Ion Trap LC/MS

Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the management of B-cell tumors and autoimmune disorders. Elementary in-silico studies were first performed to predict susceptible sites of metabolism and structural alerts...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsibaee, Aishah M., Aljohar, Haya I., Attwa, Mohamed W., Abdelhameed, Ali S., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220799/
https://www.ncbi.nlm.nih.gov/pubmed/37241965
http://dx.doi.org/10.3390/molecules28104225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220799/
https://www.ncbi.nlm.nih.gov/pubmed/37241965
http://dx.doi.org/10.3390/molecules28104225

Ejemplares similares